Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

Maria Camila Gonzalez; Diego Alejandro Tovar-Rios; Guido Alves; Ingvild Dalen; Caroline H. Williams-Gray; Marta Camacho; Lars Forsgren; David Bäckström; Rachael A. Lawson; Angus D. Macleod; Carl E. Counsell; Claire Paquet; Carlo DeLena; Fabrizia D'Antonio; Andrea Pilotto; Alessandro Padovani; Frédéric Blanc; Cristian Falup-Pecurariu; Simon J.G. Lewis; Konrad Rejdak; Ewa Papuc; Jakub Hort; Zuzana Nedelska; John O'Brien; Laura Bonanni; Marta Marquié; Mercè Boada; Vanesa Pytel; Carla Abdelnour; Daniel Alcolea; Katrin Beyer; Ole Bjørn Tysnes; Dag Aarsland; Jodi Maple-Grødem

doi:10.1002/mdc3.13752

Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

Maria Camila Gonzalez^*, Diego Alejandro Tovar-Rios, Guido Alves, Ingvild Dalen, Caroline H. Williams-Gray, Marta Camacho, Lars Forsgren, David Bäckström, Rachael A. Lawson, Angus D. Macleod, Carl E. Counsell, Claire Paquet, Carlo DeLena, Fabrizia D'Antonio, Andrea Pilotto, Alessandro Padovani, Frédéric Blanc, Cristian Falup-Pecurariu, Simon J.G. Lewis, Konrad RejdakEwa Papuc, Jakub Hort, Zuzana Nedelska, John O'Brien, Laura Bonanni, Marta Marquié, Mercè Boada, Vanesa Pytel, Carla Abdelnour, Daniel Alcolea, Katrin Beyer, Ole Bjørn Tysnes, Dag Aarsland, Jodi Maple-Grødem

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

2 Downloads (Pure)

Abstract

Background: There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD). Objectives: To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts. Methods: The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157). Results: When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (−1.8 [95% CI −2.3, −1.3] vs. −1.9 [95% CI −2.6, −1.2] [P = 0.74]). MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 [95% CI 2.1, 7.5]) (PDD 4.8 [95% CI 2.7, 6.9], [P = 0.98]). Conclusions: DLB and PDD showed similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.

Original language	English
Pages (from-to)	980-986
Number of pages	7
Journal	Movement Disorders Clinical Practice
Volume	10
Issue number	6
Early online date	18 Apr 2023
DOIs	https://doi.org/10.1002/mdc3.13752
Publication status	Published - 15 Jun 2023

Bibliographical note

Funding Information:
The University of Stavanger supported M.C.G. The CamPaIGN study has received funding from the Wellcome Trust, the Medical Research Council, the Patrick Berthoud Trust, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The ICICLE‐PD study was funded by Parkinson's UK (J‐0802, G‐1301, G‐1507) and supported by the Lockhart Parkinson's Disease Research Fund, National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit and Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The PICNICS study was funded by the Cure Parkinson's Trust, the Van Geest Foundation, the Medical Research Council, Parkinson's UK, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The NYPUM study was supported by grants from the Swedish Medical Research Council, Erling‐Persson Foundation, the Swedish Brain Foundation (Hjärnfonden), Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Swedish Parkinson Research Foundation, Kempe Foundation, Swedish PD Association, the European Research Council, and the Knut and Alice Wallenberg Foundation. The PINE study was funded by Parkinson's UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), Academy of Medical Sciences, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The PARKWEST study was supported by the Research Council of Norway (grant# 177966), the Western Norway Regional Health Authority (grant# 911218 and # 911949), Reberg legacy and the Norwegian Parkinson's Research Foundation. The PICC collaboration has been supported by The Chief Scientist Office of the Scottish Government (PCL/17/10), the Academy of Medical Sciences, Parkinson's UK (initial collaborator meeting) and the Norwegian Association for Public Health. The DEMVEST Study was supported by the regional health authorities of Western Norway, Helse‐Vest (grant# 911973). Motol University Hospital's Czech Brain Aging Study was supported by the National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107)—Funded by the European Union—Next Generation EU and by Charles University grant PRIMUS 22/MED/011. The Sant Pau Initiative on Neurodegeration (SPIN) cohort was supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473 to JF, PI13/01532 and PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 and INT19/00016 to DA, PI17/01896 and AC19/00103to AL) and the CIBERNED program (Program 1, Alzheimer Disease to AL), jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, “Una manera de hacer Europa”. It was also supported by the National Institutes of Health (NIA grants 1R01AG056850‐01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017‐SGR‐547, SLT006/17/125, SLT006/17/119, SLT002/16/408) and “Marató TV3” foundation grants 20141210, 044412 and 20142610. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsors were not involved in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication. The authors declare that there are no conflicts of interest relevant to this work. Funding Sources and Conflicts of Interest:

Keywords

dementia with Lewy bodies
international cohort
Parkinson's disease dementia
parkinsonism
rate of cognitive decline

Access to Document

10.1002/mdc3.13752Licence: CC BY

Gonzalez_etal_MD_Cognitive_and_Motor_VOR
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Final published version, 436 KBLicence: CC BY

Cite this

Gonzalez, M. C., Tovar-Rios, D. A., Alves, G., Dalen, I., Williams-Gray, C. H., Camacho, M., Forsgren, L., Bäckström, D., Lawson, R. A., Macleod, A. D., Counsell, C. E., Paquet, C., DeLena, C., D'Antonio, F., Pilotto, A., Padovani, A., Blanc, F., Falup-Pecurariu, C., Lewis, S. J. G., ... Maple-Grødem, J. (2023). Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia. Movement Disorders Clinical Practice, 10(6), 980-986. https://doi.org/10.1002/mdc3.13752

Gonzalez, MC, Tovar-Rios, DA, Alves, G, Dalen, I, Williams-Gray, CH, Camacho, M, Forsgren, L, Bäckström, D, Lawson, RA, Macleod, AD , Counsell, CE, Paquet, C, DeLena, C, D'Antonio, F, Pilotto, A, Padovani, A, Blanc, F, Falup-Pecurariu, C, Lewis, SJG, Rejdak, K, Papuc, E, Hort, J, Nedelska, Z, O'Brien, J, Bonanni, L, Marquié, M, Boada, M, Pytel, V, Abdelnour, C, Alcolea, D, Beyer, K, Tysnes, OB, Aarsland, D & Maple-Grødem, J 2023, 'Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia', Movement Disorders Clinical Practice, vol. 10, no. 6, pp. 980-986. https://doi.org/10.1002/mdc3.13752

@article{ee12e08f2feb42389b80dffde1503ccb,

title = "Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia",

abstract = "Background: There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD). Objectives: To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts. Methods: The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157). Results: When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (−1.8 [95% CI −2.3, −1.3] vs. −1.9 [95% CI −2.6, −1.2] [P = 0.74]). MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 [95% CI 2.1, 7.5]) (PDD 4.8 [95% CI 2.7, 6.9], [P = 0.98]). Conclusions: DLB and PDD showed similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.",

keywords = "dementia with Lewy bodies, international cohort, Parkinson's disease dementia, parkinsonism, rate of cognitive decline",

author = "Gonzalez, {Maria Camila} and Tovar-Rios, {Diego Alejandro} and Guido Alves and Ingvild Dalen and Williams-Gray, {Caroline H.} and Marta Camacho and Lars Forsgren and David B{\"a}ckstr{\"o}m and Lawson, {Rachael A.} and Macleod, {Angus D.} and Counsell, {Carl E.} and Claire Paquet and Carlo DeLena and Fabrizia D'Antonio and Andrea Pilotto and Alessandro Padovani and Fr{\'e}d{\'e}ric Blanc and Cristian Falup-Pecurariu and Lewis, {Simon J.G.} and Konrad Rejdak and Ewa Papuc and Jakub Hort and Zuzana Nedelska and John O'Brien and Laura Bonanni and Marta Marqui{\'e} and Merc{\`e} Boada and Vanesa Pytel and Carla Abdelnour and Daniel Alcolea and Katrin Beyer and Tysnes, {Ole Bj{\o}rn} and Dag Aarsland and Jodi Maple-Gr{\o}dem",

note = "Funding Information: The University of Stavanger supported M.C.G. The CamPaIGN study has received funding from the Wellcome Trust, the Medical Research Council, the Patrick Berthoud Trust, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The ICICLE‐PD study was funded by Parkinson's UK (J‐0802, G‐1301, G‐1507) and supported by the Lockhart Parkinson's Disease Research Fund, National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit and Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The PICNICS study was funded by the Cure Parkinson's Trust, the Van Geest Foundation, the Medical Research Council, Parkinson's UK, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The NYPUM study was supported by grants from the Swedish Medical Research Council, Erling‐Persson Foundation, the Swedish Brain Foundation (Hj{\"a}rnfonden), Ume{\aa} University, V{\"a}sterbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Swedish Parkinson Research Foundation, Kempe Foundation, Swedish PD Association, the European Research Council, and the Knut and Alice Wallenberg Foundation. The PINE study was funded by Parkinson's UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), Academy of Medical Sciences, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The PARKWEST study was supported by the Research Council of Norway (grant# 177966), the Western Norway Regional Health Authority (grant# 911218 and # 911949), Reberg legacy and the Norwegian Parkinson's Research Foundation. The PICC collaboration has been supported by The Chief Scientist Office of the Scottish Government (PCL/17/10), the Academy of Medical Sciences, Parkinson's UK (initial collaborator meeting) and the Norwegian Association for Public Health. The DEMVEST Study was supported by the regional health authorities of Western Norway, Helse‐Vest (grant# 911973). Motol University Hospital's Czech Brain Aging Study was supported by the National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107)—Funded by the European Union—Next Generation EU and by Charles University grant PRIMUS 22/MED/011. The Sant Pau Initiative on Neurodegeration (SPIN) cohort was supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473 to JF, PI13/01532 and PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 and INT19/00016 to DA, PI17/01896 and AC19/00103to AL) and the CIBERNED program (Program 1, Alzheimer Disease to AL), jointly funded by Fondo Europeo de Desarrollo Regional, Uni{\'o}n Europea, “Una manera de hacer Europa”. It was also supported by the National Institutes of Health (NIA grants 1R01AG056850‐01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017‐SGR‐547, SLT006/17/125, SLT006/17/119, SLT002/16/408) and “Marat{\'o} TV3” foundation grants 20141210, 044412 and 20142610. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsors were not involved in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication. The authors declare that there are no conflicts of interest relevant to this work. Funding Sources and Conflicts of Interest: ",

year = "2023",

month = jun,

day = "15",

doi = "10.1002/mdc3.13752",

language = "English",

volume = "10",

pages = "980--986",

journal = "Movement Disorders Clinical Practice",

issn = "2330-1619",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

AU - Gonzalez, Maria Camila

AU - Tovar-Rios, Diego Alejandro

AU - Alves, Guido

AU - Dalen, Ingvild

AU - Williams-Gray, Caroline H.

AU - Camacho, Marta

AU - Forsgren, Lars

AU - Bäckström, David

AU - Lawson, Rachael A.

AU - Macleod, Angus D.

AU - Counsell, Carl E.

AU - Paquet, Claire

AU - DeLena, Carlo

AU - D'Antonio, Fabrizia

AU - Pilotto, Andrea

AU - Padovani, Alessandro

AU - Blanc, Frédéric

AU - Falup-Pecurariu, Cristian

AU - Lewis, Simon J.G.

AU - Rejdak, Konrad

AU - Papuc, Ewa

AU - Hort, Jakub

AU - Nedelska, Zuzana

AU - O'Brien, John

AU - Bonanni, Laura

AU - Marquié, Marta

AU - Boada, Mercè

AU - Pytel, Vanesa

AU - Abdelnour, Carla

AU - Alcolea, Daniel

AU - Beyer, Katrin

AU - Tysnes, Ole Bjørn

AU - Aarsland, Dag

AU - Maple-Grødem, Jodi

N1 - Funding Information: The University of Stavanger supported M.C.G. The CamPaIGN study has received funding from the Wellcome Trust, the Medical Research Council, the Patrick Berthoud Trust, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The ICICLE‐PD study was funded by Parkinson's UK (J‐0802, G‐1301, G‐1507) and supported by the Lockhart Parkinson's Disease Research Fund, National Institute for Health Research (NIHR) Newcastle Biomedical Research Unit and Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. The PICNICS study was funded by the Cure Parkinson's Trust, the Van Geest Foundation, the Medical Research Council, Parkinson's UK, and the NIHR Cambridge Biomedical Research Centre (BRC‐1215‐20014). The NYPUM study was supported by grants from the Swedish Medical Research Council, Erling‐Persson Foundation, the Swedish Brain Foundation (Hjärnfonden), Umeå University, Västerbotten County Council, King Gustaf V and Queen Victoria Freemason Foundation, Swedish Parkinson Foundation, Swedish Parkinson Research Foundation, Kempe Foundation, Swedish PD Association, the European Research Council, and the Knut and Alice Wallenberg Foundation. The PINE study was funded by Parkinson's UK (grant numbers G0502, G0914, and G1302), the Scottish Chief Scientist Office (CAF/12/05, PCL/17/10), Academy of Medical Sciences, NHS Grampian endowments, the BMA Doris Hillier award, RS Macdonald Trust, the BUPA Foundation, and SPRING. The PARKWEST study was supported by the Research Council of Norway (grant# 177966), the Western Norway Regional Health Authority (grant# 911218 and # 911949), Reberg legacy and the Norwegian Parkinson's Research Foundation. The PICC collaboration has been supported by The Chief Scientist Office of the Scottish Government (PCL/17/10), the Academy of Medical Sciences, Parkinson's UK (initial collaborator meeting) and the Norwegian Association for Public Health. The DEMVEST Study was supported by the regional health authorities of Western Norway, Helse‐Vest (grant# 911973). Motol University Hospital's Czech Brain Aging Study was supported by the National Institute for Neurological Research (Programme EXCELES, ID Project No. LX22NPO5107)—Funded by the European Union—Next Generation EU and by Charles University grant PRIMUS 22/MED/011. The Sant Pau Initiative on Neurodegeration (SPIN) cohort was supported by the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473 to JF, PI13/01532 and PI16/01825 to RB, PI18/00335 to MCI, PI18/00435 and INT19/00016 to DA, PI17/01896 and AC19/00103to AL) and the CIBERNED program (Program 1, Alzheimer Disease to AL), jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, “Una manera de hacer Europa”. It was also supported by the National Institutes of Health (NIA grants 1R01AG056850‐01A1; R21AG056974; and R01AG061566), by Generalitat de Catalunya (2017‐SGR‐547, SLT006/17/125, SLT006/17/119, SLT002/16/408) and “Marató TV3” foundation grants 20141210, 044412 and 20142610. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The sponsors were not involved in the study design, in the collection, analysis, and interpretation of data, in the writing of the report, or in the decision to submit the article for publication. The authors declare that there are no conflicts of interest relevant to this work. Funding Sources and Conflicts of Interest:

PY - 2023/6/15

Y1 - 2023/6/15

N2 - Background: There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD). Objectives: To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts. Methods: The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157). Results: When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (−1.8 [95% CI −2.3, −1.3] vs. −1.9 [95% CI −2.6, −1.2] [P = 0.74]). MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 [95% CI 2.1, 7.5]) (PDD 4.8 [95% CI 2.7, 6.9], [P = 0.98]). Conclusions: DLB and PDD showed similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.

AB - Background: There is a need to better understand the rate of cognitive and motor decline of Dementia with Lewy bodies (DLB) and Parkinson's disease Dementia (PDD). Objectives: To compare the rate of cognitive and motor decline in patients with DLB and PDD from the E-DLB Consortium and the Parkinson's Incidence Cohorts Collaboration (PICC) Cohorts. Methods: The annual change in MMSE and MDS-UPDRS part III was estimated using linear mixed regression models in patients with at least one follow-up (DLB n = 837 and PDD n = 157). Results: When adjusting for confounders, we found no difference in the annual change in MMSE between DLB and PDD (−1.8 [95% CI −2.3, −1.3] vs. −1.9 [95% CI −2.6, −1.2] [P = 0.74]). MDS-UPDRS part III showed nearly identical annual changes (DLB 4.8 [95% CI 2.1, 7.5]) (PDD 4.8 [95% CI 2.7, 6.9], [P = 0.98]). Conclusions: DLB and PDD showed similar rates of cognitive and motor decline. This is relevant for future clinical trial designs.

KW - dementia with Lewy bodies

KW - international cohort

KW - Parkinson's disease dementia

KW - parkinsonism

KW - rate of cognitive decline

UR - http://www.scopus.com/inward/record.url?scp=85158093631&partnerID=8YFLogxK

U2 - 10.1002/mdc3.13752

DO - 10.1002/mdc3.13752

M3 - Article

C2 - 37332651

AN - SCOPUS:85158093631

SN - 2330-1619

VL - 10

SP - 980

EP - 986

JO - Movement Disorders Clinical Practice

JF - Movement Disorders Clinical Practice

IS - 6

ER -

Cognitive and Motor Decline in Dementia with Lewy Bodies and Parkinson's Disease Dementia

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this